Analytics

Feb 01, 2016
BioPharm International
The recognition that microbial artifacts are capable of modulating the mammalian immune system is an emerging view of biologic drug contamination control testing.
Feb 01, 2016
BioPharm International
Understanding of the risks associated with FMEA is crucial in lot release testing.
Feb 01, 2016
BioPharm International
Time and sensitivity are essential for analytical technologies in all phases of biopharma development.
Jan 01, 2016
BioPharm International
This article defines the concept, justification, and method of removal of out-of-trend points in stability modelling and shelf-life prediction.
Jan 01, 2016
BioPharm International
The results of an industry workgroup’s examination of EMA’s guide on shared facilities are presented.
Dec 09, 2015
Protea will use Agilent’s mass spectrometry imaging technology to develop new methods to identify cell metabolites produced as a result of disease or drug exposure.
Dec 01, 2015
BioPharm International
Advances in glycan analysis are enhancing biologics development and quality control processes.
Dec 01, 2015
BioPharm International
Expectations are high for rapid testing methods, but demonstration of comparability proves challenging.
Dec 01, 2015
BioPharm International
Mechanical tests complement visual techniques for the post-processing characterization of freeze-dried products.
Nov 30, 2015
By BioPharm International Editors
Agilent Technologies and Thermo Fisher Scientific exchange instrument control drivers and software support.
native1_300x100
lorem ipsum